Drug Profile
AGM 1470
Alternative Names: TNP 470Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Takeda
- Developer EntreMed; Takeda; TAP Pharmaceutical Products; University of Texas M. D. Anderson Cancer Center
- Class
- Mechanism of Action Aminopeptidase inhibitors; Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bladder cancer; Breast cancer; Cancer; Cervical cancer; Kaposi's sarcoma; Leukaemia; Lymphoma; Pancreatic cancer; Renal cancer
Most Recent Events
- 25 Nov 2002 Discontinued - Phase-I for Cervical cancer in USA (IV-infusion)
- 25 Nov 2002 Discontinued - Phase-I for Leukaemia in USA (unspecified route)
- 25 Nov 2002 Discontinued - Phase-I for Lymphoma in USA (unspecified route)